Search

Your search keyword '"Rosa, Gennaro"' showing total 15 results
Start Over Author "Rosa, Gennaro" Publication Year Range Last 3 years
Sorry, I don't understand your search. ×
15 results on '"Rosa, Gennaro"'

3. 349 INTRAVENOUS CANGRELOR INFUSION IN PATIENTS UNDERGOING COMPLEX VERSUS NON-COMPLEX PERCUTANEOUS CORONARY INTERVENTION: A SUBANALYSIS OF THE ICARUS REGISTRY

Author

Gragnano, Felice, primary, Benenati, Stefano, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Capolongo, Antonio, additional, De Sio, Vincenzo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Bellino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Veneziano, Francesco Antonio, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Porto, Italo, additional, and Calabrò, Paolo, additional

Published
2022
Full Text
View/download PDF

4. 330 INTRAVENOUS CANGRELOR INFUSION IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: PRELIMINARY RESULTS OF THE ICARUS REGISTRY

Author

Benenati, Stefano, primary, Gragnano, Felice, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Capolongo, Antonio, additional, Sio, Vincenzo De, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Bellino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, Luca, Leonardo De, additional, Veneziano, Francesco Antonio, additional, Cirillo, Plinio, additional, Rosa, Gennaro De, additional, Calabrò, Paolo, additional, and Porto, Italo, additional

Published
2022
Full Text
View/download PDF

5. 910 PREVALENCE AND PROGNOSTIC IMPACT OF ANAEMIA IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION AND RECEIVING CANGRELOR: A SUBANALYSIS OF THE ICARUS REGISTRY

Author

Capolongo, Antonio, primary, Gragnano, Feliceg, additional, Benenati, Stefano, additional, De Sio, Vincenzo, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Belllino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Antonio Veneziano, Francesco, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Porto, Italo, additional, and Calabrò, Paolo, additional

Published
2022
Full Text
View/download PDF

6. 345 INTRAVENOUS CANGRELOR INFUSION IN ELDERLY PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SUBANALYSIS OF THE ICARUS REGISTRY

Author

Benenati, Stefano, primary, Gragnano, Felice, additional, Capolongo, Antonio, additional, De Sio, Vincenzo, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Bellino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Antonio Veneziano, Francesco, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Calabrò, Paolo, additional, and Porto, Italo, additional

Published
2022
Full Text
View/download PDF

7. 902 INCIDENCE, CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS PRESENTING WITH VERSUS WITHOUT CARDIOGENIC SHOCK AND RECEIVING CANGRELOR: AN EXPLORATORY SUBANALYSIS OF THE ICARUS REGISTRY

Author

Scalamera, Riccardo, primary, Benenati, Stefano, additional, Gragnano, Felice, additional, Bertero, Edoardo, additional, Capolongo, Antonio, additional, De Sio, Vincenzo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Belllino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Antonio Veneziano, Francesco, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Calabrò, Paolo, additional, and Porto, Italo, additional

Published
2022
Full Text
View/download PDF

8. Uric Acid induces a pro-atherothrombotic phenotype in human endothelial cells by imbalancing TF/TFPI pathway

Author

Cimmino, Giovanni, Conte, Stefano, Marra, Laura, Morello, Andrea, Morello, Mariarosaria, De Rosa, Gennaro, Pepe, Martino, Sugralyev, Akmetzhan, Golino, Paolo, Cirillo, Plinio, Cimmino, Giovanni, Conte, Stefano, Marra, Laura, Morello, Andrea, Morello, Mariarosaria, De Rosa, Gennaro, Pepe, Martino, Sugralyev, Akmetzhan, Golino, Paolo, and Cirillo, Plinio

Abstract

Many evidences show that elevated plasma levels of uric acid (UA) are associated to the increased risk of developing athero-thrombotic cardiovascular events. Hyperuricemia is a risk factors for endothelial dysfunction (ED). ED is involved in the pathophysiology of athero-thrombosis since dysfunctional cells lose their physiological, antithrombotic properties. We have investigated whether UA might promote ED by modulating the TF/TFPI balance finally changing the antithrombotic characteristics of endothelial cells.

Published
2022

9. Uric Acid Induces a Proatherothrombotic Phenotype in Human Endothelial Cells by Imbalancing the Tissue Factor/Tissue Factor Pathway Inhibitor Pathway

Author

Cimmino, Giovanni, additional, Conte, Stefano, additional, Marra, Laura, additional, Morello, Andrea, additional, Morello, Mariarosaria, additional, De Rosa, Gennaro, additional, Pepe, Martino, additional, Sugraliyev, Akhmetzhan, additional, Golino, Paolo, additional, and Cirillo, Plinio, additional

Published
2022
Full Text
View/download PDF

11. Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?

Author

Cimmino, Giovanni, primary, Conte, Stefano, additional, Morello, Mariarosaria, additional, Pellegrino, Grazia, additional, Marra, Laura, additional, Morello, Andrea, additional, Nicoletti, Giuseppe, additional, De Rosa, Gennaro, additional, Golino, Paolo, additional, and Cirillo, Plinio, additional

Published
2022
Full Text
View/download PDF

12. Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome.

Author

Cavallari, Ilaria, Maddaloni, Ernesto, Gragnano, Felice, Patti, Giuseppe, Antonucci, Emilia, Calabrò, Paolo, Cirillo, Plinio, Gresele, Paolo, Palareti, Gualtiero, Pengo, Vittorio, Pignatelli, Pasquale, Marcucci, Rossella, the START-ANTIPLATELET collaborators, Moscarella, Elisabetta, Cesaro, Arturo, Grossi, Guido, Berteotti, Martina, De Rosa, Gennaro, Taglialatela, Vittorio, and Digitale, Lucia

Abstract

The risk of ischemic events carried by different clusters of type 2 diabetes mellitus (DM) in the setting of secondary prevention is not definite and the association between DM and bleeding complications is controversial. We explored these issues in the START-ANTIPLATELET, a multicenter Italian registry including acute coronary syndrome (ACS) patients. Study outcome was 1-year incidence of the net composite endpoint including major adverse cardiovascular events (MACE) or any bleeding and its individual components across different DM strata (no DM, DM with or without insulin). Out of 951 patients, 20.0% had diabetes not on insulin and 2.5% had diabetes on insulin. The rate of the net composite endpoint was highest in patients receiving insulin (39.4 per 100 person-years vs 11.7 in diabetic patients not on insulin vs 14.0 in those without DM; p = 0.007). In DM, the higher risk of MACE was regardless of insulin use (p = 0.36). Conversely, the increase in bleeding complications was limited to patients on insulin (Hazard Ratio 2.31, 95% CI 0.93-5.71 vs no DM; p = 0.0105 across DM strata). On top of aspirin, the rates of the net composite endpoint were similar with ticagrelor/prasugrel or clopidogrel irrespective of DM status (p for interaction 0.63). In conclusion, in ACS patients, type 2 DM enhances the risk of MACE regardless of the DM cluster, whereas the propensity to bleeding related to DM seems confined to insulin-treated patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. ACEF vs PARIS score in Predicting Cardiovascular Events in Patients With Acute Coronary Syndrome: Insights From the START ANTIPLATELET Registry.

Author

Cirillo, Plinio, Di Serafino, Luigi, Scalamogna, Maria, De Rosa, Gennaro, Calabrò, Paolo, Antonucci, Emilia, Gresele, Paolo, Palareti, Gualtiero, Patti, Giuseppe, Pengo, Vittorio, Pignatelli, Pasquale, and Marcucci, Rossella

Subjects
*ACUTE coronary syndrome, *DISEASE risk factors, *MYOCARDIAL infarction, *TREATMENT effectiveness, *VENTRICULAR ejection fraction
Abstract

Several scores can predict clinical outcomes of patients with Acute Coronary Syndromes (ACS). The validated PARIS (Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients) score is poorly used in clinical practice because it needs items that are not always easily available. The ACEF (Age, Creatinine, and Ejection Fraction) score is more attractive because it only includes three items. We compared these scores to risk-stratify ACS patients enrolled into the START (Survey on anticoagulated pAtients RegisTer)-ANTIPLATELET registry. ACS patients who completed 1-year follow-up (n = 1171) were grouped in tertiles (low, medium, and high-risk) according to their ACEF/PARIS scores. Primary endpoints were: one-year MACCE (major adverse cardiac and cerebrovascular events: death, non-fatal myocardial infarction, stroke or target vessel revascularization) and NACE (net adverse cardiac and cerebrovascular events): MACCE plus major bleeding). MACCE incidence was higher in the high-risk tertile (15%) VS low/medium (3/7 %) risk tertiles (P < .001). NACE incidence in the high-risk tertile was 24% VS low/medium (9/15 %) risk tertiles (P < .001), independently of the risk score used. The ACEF score has similar accuracy as the validated PARIS score for the estimation of ischemic/bleeding risk. Thereby, we strongly suggest its use in clinical practice to risk-stratify ACS patients and select optimal therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Uric Acid Induces a Proatherothrombotic Phenotype in Human Endothelial Cells by Imbalancing the Tissue Factor/Tissue Factor Pathway Inhibitor Pathway

Author

Giovanni Cimmino, Stefano Conte, Laura Marra, Andrea Morello, Mariarosaria Morello, Gennaro De Rosa, Martino Pepe, Akhmetzhan Sugraliyev, Paolo Golino, Plinio Cirillo, Cimmino, Giovanni, Conte, Stefano, Marra, Laura, Morello, Andrea, Morello, Mariarosaria, De Rosa, Gennaro, Pepe, Martino, Sugraliyev, Akhmetzhan, Golino, Paolo, and Cirillo, Plinio

Subjects
Hematology
Abstract

Background Several evidence show that elevated plasma levels of uric acid (UA) are associated with the increased risk of developing atherothrombotic cardiovascular events. Hyperuricemia is a risk factor for endothelial dysfunction (ED). ED is involved in the pathophysiology of atherothrombosis since dysfunctional cells lose their physiological, antithrombotic properties. We have investigated whether UA might promote ED by modulating the tissue factor (TF)/TF pathway inhibitor (TFPI) balance by finally changing the antithrombotic characteristics of endothelial cells. Methods Human umbilical vein endothelial cells were incubated with increasing doses of UA (up to 9 mg/dL). TF gene and protein expressions were evaluated by real-time polymerase chain reaction (PCR) and Western blot. Surface expression and procoagulant activity were assessed by FACS (fluorescence activated cell sorting) analysis and coagulation assay. The mRNA and protein levels of TFPI were measured by real-time PCR and Western blot. The roles of inflammasome and nuclear factor-κB (NF-κB) as possible mechanism(s) of action of the UA on TF/TFPI balance were also investigated. Results UA significantly increased TF gene and protein levels, surface expression, and procoagulant activity. In parallel, TFPI levels were significantly reduced. The NF-κB pathways appeared to be involved in modulating these phenomena. Additionally, inflammasome might also play a role. Conclusion The present in vitro study shows that one of the mechanisms by which high levels of UA contribute to ED might be the imbalance between TF/TFPI levels in endothelial cells, shifting them to a nonphysiological, prothrombotic phenotype. These UA effects might hypothetically explain, at least in part, the relationship observed between elevated plasma levels of UA and cardiovascular events.

Published
2022

15. Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence

Author

Giovanni Cimmino, Francesco S. Loffredo, Gennaro De Rosa, Plinio Cirillo, Cimmino, G., Loffredo, F. S., De Rosa, G., Cirillo, P., Cimmino, Giovanni, Loffredo, Francesco S, De Rosa, Gennaro, and Cirillo, Plinio

Subjects
Inorganic Chemistry, cardiovascular disease, inflammation, Organic Chemistry, General Medicine, Physical and Theoretical Chemistry, Molecular Biology, Spectroscopy, Catalysis, colchicine, Computer Science Applications
Abstract

Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Mediterranean fever. To date, current guidelines of the European Society of Cardiology have included colchicine as first line choice for treatment of acute and recurrent pericarditis. Moreover, several studies have investigated its role in the clinical scenarios of cardiovascular disease including chronic and acute coronary syndromes with promising results. In this review, starting from a description of the mechanism(s) involved behind its anti-inflammatory effects, we give an overview on its potential effects in atherothrombosis and finally present an updated overview of clinical evidence on the role of this drug in cardiovascular disease.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results